Rhenman & Partners Asset Management AB Purchases 52,500 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Rhenman & Partners Asset Management AB boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 56.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 145,500 shares of the specialty pharmaceutical company's stock after buying an additional 52,500 shares during the quarter. Jazz Pharmaceuticals accounts for about 1.8% of Rhenman & Partners Asset Management AB's investment portfolio, making the stock its 21st largest position. Rhenman & Partners Asset Management AB owned approximately 0.24% of Jazz Pharmaceuticals worth $17,918,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after purchasing an additional 100,112 shares during the period. Centre Asset Management LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $9,335,000. Moloney Securities Asset Management LLC purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at about $464,000. Franklin Resources Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after buying an additional 48,708 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals by 13.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company's stock worth $4,420,000 after acquiring an additional 4,332 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Activity

In other news, CMO Robert Iannone sold 7,080 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the transaction, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. The trade was a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,736 shares of company stock valued at $4,023,305. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ traded down $10.28 during mid-day trading on Thursday, hitting $99.84. 1,088,029 shares of the company's stock traded hands, compared to its average volume of 771,864. The firm has a market capitalization of $6.06 billion, a price-to-earnings ratio of 14.04, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The firm has a 50 day moving average of $130.49 and a two-hundred day moving average of $122.78. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research analyst reports. Morgan Stanley restated an "overweight" rating and issued a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Barclays reiterated an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Finally, Royal Bank of Canada dropped their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has an average rating of "Buy" and a consensus price target of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.